Overview

A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Participants With Thyroid Eye Disease

Status:
Recruiting
Trial end date:
2026-05-04
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of subcutaneous satralizumab, a recombinant, humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody, in participants with thyroid eye disease (TED).
Phase:
Phase 3
Details
Lead Sponsor:
Hoffmann-La Roche